Active — Not RecruitingNot Applicable

Change in the Proportion of Correct Interpretations of Pulmonary Opacities

Colombia50 participantsStarted 2026-07-01

Plain-language summary

This randomized crossover clinical trial will evaluate whether an artificial intelligence-based expert system improves the interpretation of chest radiographs by final-year medical students, rural physicians, and general practitioners with less than two years of clinical experience. Participants will interpret chest radiographs containing normal findings or pulmonary opacities classified as alveolar, interstitial, or mixed. Each participant will review the same set of radiographs twice: once without assistance from the expert system and once with assistance from the artificial intelligence system. The order of these two reading conditions will be randomly assigned, with a six-week interval between sessions to reduce memory effects. The main outcome will be the proportion of correct interpretations compared with a previously established reference standard based on radiologist interpretation supported by chest computed tomography findings. The study will also assess diagnostic confidence and agreement with the reference standard. This study does not involve treatment decisions or direct patient care. It is intended to determine whether artificial intelligence support may improve the accuracy and confidence of less-experienced physicians when interpreting pulmonary opacities on chest radiographs.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Final-year undergraduate medical students. * Physicians completing mandatory rural or social service. * Licensed general practitioners with less than two years of clinical experience. * Willingness to participate as a chest radiograph reader. * Ability to complete both study reading sessions. Exclusion Criteria: * Corrected visual acuity worse than 20/60 in the better-seeing eye. * Visual-field restriction, impaired contrast perception, binocular vision abnormalities, or another visual condition that prevents adequate interpretation of chest radiographs. * Inability to complete the visual acuity assessment before the reading session.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of globally correct interpretations of pulmonary opacities

Timeframe: Each of the two reading sessions, separated by a 6-week washout period

Trial details

NCT IDNCT07744555

SponsorUniversidad de la Sabana

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10

View on ClinicalTrials.gov More Pneumonia trials